ALLO
Allogene Therapeutics Inc

3,212
Loading...
Loading...
News
all
press releases
Why Is Allogene Therapeutics (ALLO) Up 9.4% Since Last Earnings Report?
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·10h ago
News Placeholder
More News
News Placeholder
Investing in Oncology: 3 Cancer Stocks With Promising Pipelines
Relay Therapeutics, Pyxis Oncology and Allogene Therapeutics drive cancer innovation with pivotal trials and promising drug candidates.
Zacks·4d ago
News Placeholder
AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA
Aquestive Therapeutics shares surge after FDA skips advisory meeting on Anaphylm NDA, keeping its January 2026 action date intact.
Zacks·7d ago
News Placeholder
AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia
Agios shares tank as the FDA extends the review period for Pyrukynd in thalassemia by three months, pushing the final ruling to Dec. 7, 2025.
Zacks·7d ago
News Placeholder
Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus
ALLO posts a narrower second-quarter 2025 loss. The company advances multiple CAR T programs targeting cancer and autoimmune diseases.
Zacks·29d ago
News Placeholder
Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025
J&J, Novartis and Allogene Therapeutics are making bold oncology moves as demand surges for next-generation cancer therapies.
Zacks·2mo ago
News Placeholder
Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report?
Zacks·3mo ago
News Placeholder
All You Need to Know About Allogene Therapeutics (ALLO) Rating Upgrade to Buy
Zacks·3mo ago
News Placeholder
REGN Signs $256M Buyout Deal With 23andMe to Boost Genomics Research
Zacks·4mo ago
News Placeholder
Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus
Zacks·4mo ago

Latest ALLO News

View

Advertisement. Remove ads.

Advertisement. Remove ads.